arrow
A

Akihiko Gemma

nippon medical school
H指数:55
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time

J-TAIL-2研究结果的简明摘要:一项关于日本广泛期小细胞肺癌患者接受阿替利珠单抗联合化疗长期随访的研究

2026-10-010
OA
Quantitative evaluation of healthcare information provided to patients with thoracic malignancies: patient satisfaction survey of the Japan Lung Cancer Society

对胸癌患者提供医疗信息的定量评估:日本肺癌协会患者满意度调查

2026-05-270
PRE
Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study

日本AYAME多中心前瞻性研究中,接受化疗联合放疗后使用度鲁万治疗不可切除III期非小细胞肺癌患者的间质性肺病

2026-05-190
OAAI
Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2

J-TAIL-2研究中接受阿替利珠单抗联合疗法治疗的肺癌患者血浆蛋白质组学分析用于生物标志物发现

2026-04-010
OAAI
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab

阿特珠单抗治疗晚期NSCLC患者外周血T细胞谱及血浆蛋白质组学分析

2026-02-020
OAAI
Atezolizumab plus Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)

阿特珠单抗联合化疗治疗日本临床实践中晚期非小细胞肺癌(J-TAIL-2)

2025-12-010
OAAI
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)

日本不可切除性III期非小细胞肺癌中 durvalumab 的长期安全性和有效性:一项多中心前瞻性研究(AYAME)

2025-08-180
OAAI
J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
2025-03-010
OA
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL
2024-07-011
OA
Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC : A Multicenter, Prospective, Observational Study (J-TAIL)
2023-03-0110
OA
Identification and characterization of lysophosphatidylcholine 14:0 as a biomarker for drug-induced lung disease
2022-11-1711
OAAI
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

使用日本上市后所有病例监测数据对Pembrolizumab单药治疗NSCLC的真实数据分析

2022-11-013
OA
Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage
2022-10-047
OAAI
Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society

创建综合临床试验数据库和数据共享,以进行日本肺癌学会的新研究

2022-05-012
OA